Acuta Capital Partners LLC Invests $2.44 Million in COMPASS Pathways plc (NASDAQ:CMPS)

Acuta Capital Partners LLC acquired a new stake in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 386,500 shares of the company's stock, valued at approximately $2,435,000. COMPASS Pathways accounts for approximately 2.0% of Acuta Capital Partners LLC's investment portfolio, making the stock its 18th biggest holding. Acuta Capital Partners LLC owned about 0.56% of COMPASS Pathways at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of CMPS. Blue Trust Inc. acquired a new position in COMPASS Pathways during the 2nd quarter worth approximately $81,000. Green Alpha Advisors LLC purchased a new position in shares of COMPASS Pathways in the third quarter valued at $99,000. Kennedy Capital Management LLC acquired a new stake in COMPASS Pathways during the 1st quarter valued at $139,000. Tidal Investments LLC increased its stake in COMPASS Pathways by 43.6% during the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company's stock worth $159,000 after buying an additional 5,795 shares during the period. Finally, Virtu Financial LLC acquired a new position in COMPASS Pathways in the 1st quarter worth $201,000. Institutional investors and hedge funds own 46.19% of the company's stock.

COMPASS Pathways Stock Performance

NASDAQ CMPS traded up $0.04 during trading hours on Thursday, reaching $4.56. The company's stock had a trading volume of 430,734 shares, compared to its average volume of 632,570. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The business has a 50-day simple moving average of $5.74 and a 200 day simple moving average of $6.61. COMPASS Pathways plc has a 52 week low of $4.05 and a 52 week high of $12.75. The stock has a market cap of $312.00 million, a PE ratio of -2.07 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same period in the prior year, the company posted ($0.67) earnings per share. Equities research analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

Insider Transactions at COMPASS Pathways

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the transaction, the insider now directly owns 6,905,774 shares of the company's stock, valued at $41,779,932.70. This represents a 27.81 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.25% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Canaccord Genuity Group dropped their target price on COMPASS Pathways from $50.00 to $48.00 and set a "buy" rating on the stock in a research report on Friday, August 2nd. Maxim Group cut their target price on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. HC Wainwright decreased their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Royal Bank of Canada reduced their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $30.67.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.